# To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)

> **NCT03472287** · PHASE1 · COMPLETED · sponsor: **Castle Creek Pharmaceuticals, LLC** · enrollment: 11 (actual)

## Conditions studied

- Epidermolysis Bullosa (EB)
- Epidermolysis Bullosa Simplex
- Dystrophic Epidermolysis Bullosa
- Junctional Epidermolysis Bullosa

## Interventions

- **DRUG:** Diacerein 1% Ointment

## Key facts

- **NCT ID:** NCT03472287
- **Lead sponsor:** Castle Creek Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-18
- **Primary completion:** 2019-01-31
- **Final completion:** 2019-02-14
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2020-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03472287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03472287, "To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03472287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*